Zai Lab says zoci posts 53.7% intracranial response rate in SCLC brain metastases trial

• Zai Lab disclosed new early-stage clinical results for zocilurtatug pelitecan, a DLL3-targeting antibody-drug conjugate being developed for small cell lung cancer with brain metastases.
• Findings were presented as showing rapid intracranial tumor shrinkage in previously treated patients, with responses seen across dose levels.
• Separate early data in extrapulmonary neuroendocrine carcinomas indicated meaningful anti-tumor activity in heavily pretreated patients.
• Detailed datasets will be presented at AACR Annual Meeting 2026, with an investor call scheduled for April 20, 2026.
• Zai Lab is running a global Phase 3 trial in second-line-plus small cell lung cancer, with first-line small cell lung cancer and neuroendocrine carcinoma programs moving toward registrational-stage studies in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604171501BIZWIRE_USPR_____20260417_BW034173) on April 17, 2026, and is solely responsible for the information contained therein.